MGMT and neoplasm: Among patients with a tumor harboring MGMT promoter methylation in the ITT population (ITT/mMGMT), OS was not statistically different (median OS 29.4 months (95% CI, 20.7–32.1) in the marizomib arm and 25.5 months (95% CI, 21.1–31.3) in the standard arm; stratified HR = 0.86; 95% CI, 0.60–1.24, stratified log-rank: P = 0.41) (Figure 3B).